Jiuwang Pharmaceutical

SPH Holding (Hunan) Co., Ltd. is a pharmaceutical distribution center in the Hunan region, established through investment by SPH Holding Co., Ltd. The company is located at Floor 20, Building A, Lugu Information Port, No. 658 Lugu Avenue, High-tech Development Zone, Yuelu District, Changsha City, with registered capital of 332.87 million yuan and an office and warehouse area of 24,000 square meters. According to the company's development plan, approximately 120 million yuan has been invested in the Changsha Yuelu Science and Technology Industrial Park to build a high-tech pharmaceutical logistics park integrating standardized, automated, comprehensive and efficient functions, which has now been relocated to the new site and put into use. The company mainly deals in narcotic drugs, Class I and Class II psychotropic drugs, Chinese medicinal materials, Chinese patent medicines, traditional Chinese medicine decoction pieces, chemical raw materials and their preparations, antibiotic raw materials and their preparations, etc. The company has a management team that is enterprising, united and stable, and a workforce full of passion and dedication. It has established a complete enterprise resource management (ERP) information system covering the entire process of drug procurement, storage, sales and transportation, providing comprehensive support for enterprise operation and management. Modern logistics is equipped with intelligent facilities and equipment such as WMS warehouse information system, electronic tags, barcode systems, cold chain monitoring, and GPS positioning. The company's sales network has covered all prefecture-level cities and prefectures in Hunan, including more than 120 hospitals at or above Grade II, more than 30 Grade III hospitals, and over ten ministerial-level hospitals, with a hospital coverage rate in Hunan of over 65%. The company has established good cooperative relationships with more than 2,000 pharmaceutical factories and suppliers nationwide, and has established long-term and stable supply relationships with more than 3,000 drug-using units. In 2021, the company is committed to building a provincial-level platform in Hunan. It has currently established SPH Holding (Xiangxi) Co., Ltd., SPH Holding (Yiyang) Co., Ltd., SPH Holding (Huaihua) Co., Ltd., SPH Holding (Shaoyang) Co., Ltd., SPH Holding (Yueyang) Co., Ltd., SPH Holding (Hengyang) Co., Ltd., SPH Medical Devices (Changsha) Co., Ltd., and SPH Holding (Hunan) Biological Products Co., Ltd., and plans to complete the strategic layout of subsidiaries in 14 prefecture-level cities and prefectures within the province by 2025, striving to achieve a sales scale of 5 billion by 2025. The company closely revolves around the development strategy of SPH Holding, accelerates provincial-regional operation integration, and deepens the regional leadership strategy. Relying on the brand influence, product resource advantages and leading management system of Shanghai Pharmaceuticals, in the historic period of reform and development of the pharmaceutical distribution industry, it actively explores innovation in business formats and development models, takes business innovation, service innovation and lean management as its grasp, takes meeting customer needs as its purpose, and serves customers and contributes to society.